
Veronika J. Wirtz, PhD, MSc
Professor, Global Health - Boston University School of Public Health
Biography
Veronika J. Wirtz, MSc, PhD is a Professor in the Department of Global Health at the Boston University School of Public Health, where she is also Director of the World Health Organization Collaborating Center in Pharmaceutical Policy. Her research focuses on health system strengthening and policy and program evaluations of medicines access and utilization. She is a Visiting Professor of the National Institute of Public Health (INSP) in Mexico.
Her interest and expertise include medicines price analysis, generic medicines policies, quality use of medicines, access to medicines for non-communicable diseases and the role of the private sector to promote equitable access and efficient use of medicines in low and middle income countries. Among other international studies Dr Wirtz carried out cross-national comparison of medicines consumption using large sales data bases to inform policy making about adequate use of medicines and prevention of antimicrobial resistance.
Between 2014 and 2016 she was the Co-Chair of The Lancet Commission on Essential Medicine Policies. The Commission had the goals of (1) re-confirming the ongoing relevance, and the crucial need of comprehensive essential medicines policies to achieve broader global health and sustainable development goals, especially universal health coverage and (2) formulating recommendations for global essential medicine policies for the next two decades. The Report of the Commission Essential Medicines for Universal Coverage was published in 2016.
From 2004 to 2012 she was researcher and lecturer at the National Institute of Public Health (INSP) in Mexico and a founding member and Head of the Medicines in Public Health Research Group which is a multi-disciplinary team of 15 experts in health economics, epidemiology, social science carrying out pharmaceutical policy analysis in Mexico and Latin America. Over the last years she has regularly taught short courses in Pharmacoepidemiology and Medicines Utilization Research at INSP in Mexico.
She has worked as a technical adviser for various international organizations, among them the World Health Organization, the Pan American Health Organization, the World Bank, the Global Fund to fight AIDS, Tuberculosis and Malaria, the Bill and Melinda Gates Foundation, Alliance for Health Systems and Policy Research, Health Action International and the Ford Foundation. She has also worked with the Ministry of Health in Mexico on various program evaluations and capacity building initiatives. She published widely in international peer review journals such as The Lancet, British Medical Journal, World Health Organization Bulletin, Health Policy and Planning, Health Policy, Value in Health, Social Science and Medicine, Tropical Medicine and International Health. Since Fall 2016 she is Associate Editor of Health Systems & Reform, a leading journal publishing health system and policy research.
She received her training as a pharmacist from Albert-Ludwigs-University in Freiburg, Germany and her Master in Clinical Pharmacy and PhD from the University of London in the UK.
Education
- University of London, PhD Field of Study: Pharmaceutical Policy
- University of London, MSc Field of Study: Pharmacy
- Albert-Ludwigs-Universität Freiburg, BS Field of Study: Pharmacy
Websites
Classes Taught
- SPHGH722
- SPHGH888
- SPHGH941
Publications
- Published on 9/1/2023
Thrasher R, Kaplan W, Wirtz VJ, Clear L, Bodduluri SP, Polaski S. Policy responses to COVID-19: lessons for the global trade and investment regime. Global Health. 2023 Sep 01; 19(1):66. PMID: 37658444.
Read At: PubMed
- Published on 6/19/2023
Rockers PC, Kiragu ZW, Onyango MA, Laing RO, Wirtz VJ. Willingness to pay brand premiums for generic medicines in Kenya: A bidding game experiment. Int J Health Plann Manage. 2023 Sep; 38(5):1453-1463. PMID: 37337315.
Read At: PubMed
- Published on 6/3/2023
Joosse IR, Wirtz VJ, van Mourik AT, Wagner BA, Mantel-Teeuwisse AK, Suleman F, van den Ham HA. SDG indicator 3.b.3 - an analysis of its robustness and challenges for measuring access to medicines for children. BMC Health Serv Res. 2023 Jun 03; 23(1):574. PMID: 37270535.
Read At: PubMed
- Published on 6/1/2023
Wirtz VJ, Millán-Garduño G, Hegewisch-Taylor J, Dreser A, Anaya-Sanchez A, González-Vázquez TT, Escalera R, Torres-Pereda P. Misinformation messages shared via WhatsApp in Mexico during the COVID-19 pandemic: an exploratory study. Health Promot Int. 2023 Jun 01; 38(3). PMID: 37140349.
Read At: PubMed
- Published on 5/3/2023
Chen TC, Wettermark B, Steinke D, Caughey GE, Tadrous M, Wirtz VJ, Chen LC. Feasibility and validity of using healthcare databases to conduct cross-national comparative studies of opioid use, its determinants and consequences. Pharmacoepidemiol Drug Saf. 2023 Sep; 32(9):1021-1031. PMID: 36942801.
Read At: PubMed
- Published on 5/2/2023
Kaplan WA, Cellini CM, Eghan K, Pilz K, Harrison D, Wirtz VJ. Contracting retail pharmacies as a source of essential medicines for public sector clients in low- and middle-income countries: a scoping review of key considerations, challenges, and opportunities. J Pharm Policy Pract. 2023 May 02; 16(1):60. PMID: 37131256.
Read At: PubMed
- Published on 5/1/2023
Requejo Domínguez JA, Mino-León D, Wirtz VJ. Quality of clinical evidence and political justifications of ivermectin mass distribution of COVID-19 kits in eight Latin American countries. BMJ Glob Health. 2023 May; 8(5). PMID: 37225261.
Read At: PubMed
- Published on 3/21/2023
Chen TC, Wettermark B, Steinke D, Caughey GE, Tadrous M, Wirtz VJ, Chen LC. Feasibility and validity of using healthcare databases to conduct cross-national comparative studies of opioid use, its determinants and consequences. Pharmacoepidemiol Drug Saf. 2023 Mar 21. PMID: 36942801.
Read At: PubMed
- Published on 11/9/2022
Orubu ESF, Samad MA, Rahman MT, Zaman MH, Wirtz VJ. The integrity of the antimicrobial supply chain in Bangladesh: assessing the regulatory environment and contextual challenges. J Public Health Policy. 2022 Dec; 43(4):640-658. PMID: 36352259.
Read At: PubMed
- Published on 11/1/2022
Perehudoff K, Wirtz VJ, Wong A, Rusu V, Kohler J. A global social contract to ensure access to essential medicines and health technologies. BMJ Glob Health. 2022 Nov; 7(11). PMID: 36368767.
Read At: PubMed
View 174 more publications:View Full Profile at BUMC
News & In the Media
-
Published on April 7, 2022
Emerging Women Leaders Program Promotes Diversity in Public Health Leadership
-
Published on November 6, 2020
Emerging Women Leaders Program Addresses Gap in Career Mentorship
-
Published on October 28, 2020
Pharma Companies Are Investing in Social Good. Could They Do Better?
- Published on August 27, 2020
- Published on August 17, 2020
-
Published on August 13, 2020
‘It’s More Difficult for the Global Community to Address COVID If We Keep Secrets’
- Published on August 1, 2019
-
Published on July 29, 2019
Drug Prices: Trump Trade Deal Would Boost Prescription Prices
- Published on June 24, 2019
- Published on March 26, 2019
-
Published on March 5, 2019
First Experimental Evaluation of Pharmaceutical Industry-Led Access Program
-
Published on February 14, 2019
Access to Healthcare Is Not Enough — High Quality Care Has to Be the Target
-
Published on July 16, 2018
Tracking Scope and Impact of Pharmaceutical Companies’ Social Investment
-
Published on March 27, 2018
Clinical Depression Underdiagnosed in Mexican Female Teachers
- Published on January 3, 2018
-
Published on June 12, 2017
In Mexico, Students Tackle Cavities, Pesticides, Sex Ed, and More
- Published on April 13, 2017
- Published on March 20, 2017
- Published on January 18, 2017
-
Published on November 8, 2016
In Essential Medicines Access, Progress and Challenges Around the World
-
Published on May 24, 2016
Exchanging Students and Ideas with Mexican Public Health Institute
-
Published on March 18, 2016
Former Pharmacist Studies Home Country’s Medicines Management
- Published on March 16, 2016